{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T12:20:57Z","timestamp":1753359657753},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T00:00:00Z","timestamp":1524182400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10147-018-1280-9","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T03:45:53Z","timestamp":1524195953000},"page":"930-935","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma"],"prefix":"10.1007","volume":"23","author":[{"given":"Yuji","family":"Takei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzuyo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuo","family":"Machida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyo","family":"Taneichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yoshiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Saga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,20]]},"reference":[{"key":"1280_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3322\/caac.21395","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:177\u2013193","journal-title":"CA Cancer J Clin"},{"key":"1280_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrclinonc.2015.26","volume":"12","author":"AM Nick","year":"2015","unstructured":"Nick AM, Coleman RL, Ramirez PT et al (2015) A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol 12:239\u2013245","journal-title":"Nat Rev Clin Oncol"},{"key":"1280_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","volume":"374","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3\u00a0weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:1331\u20131338","journal-title":"Lancet"},{"key":"1280_CR4","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483","journal-title":"N Engl J Med"},{"key":"1280_CR5","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484\u20132496","journal-title":"N Engl J Med"},{"key":"1280_CR6","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","volume":"88","author":"T Sugiyama","year":"2000","unstructured":"Sugiyama T, Kamura T, Kigawa J et al (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584\u20132589","journal-title":"Cancer"},{"key":"1280_CR7","first-page":"951","volume":"10","author":"Y Takei","year":"2003","unstructured":"Takei Y, Suzuki M, Ohwada M et al (2003) A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer. Oncol Rep 10:951\u2013955","journal-title":"Oncol Rep"},{"key":"1280_CR8","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/sj.bjc.6603116","volume":"94","author":"M Takano","year":"2006","unstructured":"Takano M, Kikuchi Y, Yaegashi N et al (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94:1369\u20131374","journal-title":"Br J Cancer"},{"key":"1280_CR9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1097\/IGC.0b013e3182856736","volume":"23","author":"H Mahdi","year":"2013","unstructured":"Mahdi H, Moslemi-Kebria M, Levinson KL et al (2013) Prevalence and prognostic impact of lymphadenectomy and lymph node metastasis in clinically early-stage ovarian clear cell carcinoma. Int J Gynecol Cancer 23:1226\u20131230","journal-title":"Int J Gynecol Cancer"},{"key":"1280_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/IGC.0000000000000559","volume":"26","author":"JJ Mueller","year":"2016","unstructured":"Mueller JJ, Holzapfel M, Han CH et al (2016) Staging lymphadenectomy in patients with clear cell carcinoma of the ovary. Int J Gynecol Cancer 26:120\u2013124","journal-title":"Int J Gynecol Cancer"},{"key":"1280_CR11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/IGC.0b013e3181a83f4f","volume":"19","author":"M Takano","year":"2009","unstructured":"Takano M, Sugiyama T, Yaegashi N et al (2009) The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study. Int J Gynecol Cancer 19:1353\u20131357","journal-title":"Int J Gynecol Cancer"},{"key":"1280_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"1280_CR13","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1200\/JCO.2016.66.9010","volume":"34","author":"T Sugiyama","year":"2016","unstructured":"Sugiyama T, Okamoto A, Enomoto T et al (2016) Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017\/GCIG trial. J Clin Oncol 34:2881\u20132887","journal-title":"J Clin Oncol"},{"key":"1280_CR14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3892\/ol.2012.853","volume":"4","author":"S Machida","year":"2012","unstructured":"Machida S, Sato T, Fujiwara H et al (2012) Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma. Oncol Lett 4:1017\u20131022","journal-title":"Oncol Lett"},{"key":"1280_CR15","first-page":"498","volume":"79","author":"PB Panici","year":"1992","unstructured":"Panici PB, Scambia G, Baiocchi G et al (1992) Anatomical study of para-aortic and pelvic lymph nodes in gynecologic malignancies. Obstet Gynecol 79:498\u2013502","journal-title":"Obstet Gynecol"},{"key":"1280_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ygyno.2007.01.028","volume":"105","author":"A Pereira","year":"2007","unstructured":"Pereira A, Magrina JF, Rey V et al (2007) Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol Oncol 105:604\u2013608","journal-title":"Gynecol Oncol"},{"key":"1280_CR17","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1200\/JCO.2017.35.15_suppl.5500","volume":"35","author":"P Harter","year":"2017","unstructured":"Harter P, Sehouli J, Lorusso D et al (2017) LION: Lymphadenectomy in ovarian neoplasms\u2014a prospective randomized AGO study group led gynecologic cancer intergroup trial. J Clin Oncol 35:5500","journal-title":"J Clin Oncol"},{"key":"1280_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/his.12033","volume":"62","author":"A Gurung","year":"2013","unstructured":"Gurung A, Hung T, Morin J et al (2013) Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology 62:59\u201370","journal-title":"Histopathology"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-018-1280-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1280-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1280-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T23:52:17Z","timestamp":1555717937000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-018-1280-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,20]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1280"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1280-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,20]]},"assertion":[{"value":"20 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}